|
gptkbp:instanceOf
|
gptkb:alkaloid
gptkb:anticholinergic_drug
|
|
gptkbp:administeredBy
|
injection
oral tablet
transdermal patch
|
|
gptkbp:affiliatedWith
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:alsoKnownAs
|
scopolamine
|
|
gptkbp:ATCCode
|
A03BA03
|
|
gptkbp:brand
|
Buscopan
Hyoscine butylbromide
Hyoscine hydrobromide
Kwells
Scopoderm
Transderm Scop
|
|
gptkbp:CASNumber
|
51-34-3
|
|
gptkbp:chemicalFormula
|
C17H21NO4
|
|
gptkbp:contraindication
|
gptkb:glaucoma
prostatic hypertrophy
|
|
gptkbp:discoveredBy
|
gptkb:Albert_Ladenburg
|
|
gptkbp:discoveredIn
|
1880
|
|
gptkbp:eliminationHalfLife
|
8 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:foundIn
|
plants of the Solanaceae family
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
muscarinic acetylcholine receptor antagonist
|
|
gptkbp:meltingPoint
|
59–61 °C
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
303.35 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
subcutaneous
transdermal
intravenous
|
|
gptkbp:sideEffect
|
blurred vision
drowsiness
dry mouth
urinary retention
|
|
gptkbp:UNII
|
7M19JJG44Q
|
|
gptkbp:usedFor
|
motion sickness
postoperative nausea and vomiting
gastrointestinal spasms
|
|
gptkbp:bfsParent
|
gptkb:Skopolamin
gptkb:Scopolamine
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
hyoscine
|